Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges in Ras therapeutics in pancreatic cancer.

Seminars in cancer biology - 1 Feb 2019

Choi Minsig, Bien Harold, Mofunanya Adaobi, Powers Scott

Abstract excerpt

Pancreatic cancer is considered among the most aggressive and the least curable of all human malignancies. It is usually characterized by multiple aberrations in tumor suppressor genes and oncogenes, most notably activating mutations in KRAS. This review examines the various attempts that have been made to inhibit Kras and its downstream signaling pathways in pancreatic cancer with an emphasis on challenges...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Drug Discovery
Share to Mitogen-Activated Protein Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Oncogene Proteins

Share to Oncogenes

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins c-akt

Source

Identifiers

PMID: 29170065
DOI: 10.1016/j.semcancer.2017.11.015

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges in Ras therapeutics in pancreatic cancer.PMID 29170065Read ↗

Targeting KRAS in pancreatic cancer: new drugs on the horizon.Semantic proximity Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming.Semantic proximity Read ↗

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.Semantic proximity Read ↗

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentSemantic proximity Read ↗

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read ↗

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).Semantic proximity Read ↗

KRAS mutation in pancreatic cancer.Semantic proximity Read ↗

Emerging role of the KRAS-PDK1 axis in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.